In conclusion, this study provides early evidence supporting a role for FGFR4 in LAM and sets the foundation for hypothesis-driven research to further elucidate its impact on disease progression and potential as a therapeutic target. Here, FGFR4 is linked to lymphangioleiomyomatosis.